| Autor: |
Lalezari, S, Chou, AP, Tran, A, Solis, OE, Khanlou, N, Chen, W, Li, S, Carrillo, JA, Chowdhury, R, Selfridge, J, Sanchez, DE, Wilson, RW, Zurayk, M, Lalezari, J, Lou, JJ, Ormiston, L, Ancheta, K, Hanna, R, Miller, P, Piccioni, D, Ellingson, BM, Buchanan, C, Mischel, PS, Nghiemphu, PL, Green, R, Wang, HJ, Pope, WB, Liau, LM, Elashoff, RM, Cloughesy, TF, Yong, WH, Lai, A |
| Jazyk: |
angličtina |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
Lalezari, S; Chou, AP; Tran, A; Solis, OE; Khanlou, N; Chen, W; et al.(2013). Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology, 15(3), 370-381. doi: 10.1093/neuonc/nos308. UCLA: Retrieved from: http://www.escholarship.org/uc/item/5fc2v4np |
| DOI: |
10.1093/neuonc/nos308. |
| Popis: |
BackgroundPromoter methylation of the DNA repair gene, O-6-methylguanine- DNA methyltransferase (MGMT), is associated with improved treatment outcome for newly diagnosed glioblastoma (GBM) treated with standard chemoradiation. To determine the prognostic significance of MGMT protein expression as assessed by immunohistochemistry (IHC) and its relationship with methylation, we analyzed MGMT expression and promoter methylation with survival in a retrospective patient cohort.MethodsWe identified 418 patients with newly diagnosed GBM at University of California Los Angeles Kaiser Permanente Los Angeles, nearly all of whom received chemoradiation, and determined MGMT expression by IHC, and MGMT promoter methylation by methylation-specific PCR (MSP) and bisulfite sequencing (BiSEQ) of 24 neighboring CpG sites.ResultsWith use of the median percentage of cells staining by IHC as the threshold, patients with |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
